Ironwood Pharmaceuticals (IRWD) Non Operating Income (2010 - 2026)

Ironwood Pharmaceuticals (IRWD) has 17 years of Non Operating Income data on file, last reported at -$7.4 million in Q1 2026.

• For the quarter ending Q1 2026, Non Operating Income fell 3.31% year-over-year to -$7.4 million; the trailing twelve-month figure through Mar 2026 stood at -$28.7 million (up 1.08% YoY), and the FY2025 full-year result was -$28.5 million, down 1.97% from the prior year.
• Non Operating Income declined to -$7.4 million in Q1 2026, from -$6.4 million in the prior quarter.
• In the past five years, Non Operating Income ranged from a high of $6.9 million in Q2 2023 to a low of -$8.3 million in Q3 2024.
• A 5-year average of -$3.8 million and a median of -$6.4 million in 2025 frame the typical range for Non Operating Income.
• Peak annual rise in Non Operating Income reached 517.38% in 2023, while the deepest fall reached 664.23% in 2023.
• Tracing IRWD's Non Operating Income over 5 years: stood at $3.9 million in 2022, then plunged by 285.26% to -$7.2 million in 2023, then decreased by 3.69% to -$7.5 million in 2024, then gained by 15.29% to -$6.4 million in 2025, then slipped by 16.55% to -$7.4 million in 2026.
• Business Quant data shows IRWD's Non Operating Income at -$7.4 million in Q1 2026, -$6.4 million in Q4 2025, and -$7.5 million in Q3 2025.